Products for Research Use Only
RegisterLogin

CMF9

CAT: 0804-HY-P11223Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P11223Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
CMF9, a cyclic peptide molecule, is an inhibitor of the SMAD2-SMAD4 interaction. CMF9 effectively blocks the formation of the heterodimeric complex of SMAD2 and SMAD4 by inhibiting the phosphorylation of SMAD2. CMF9 has no effect on the phosphorylation of SMAD3 or SMAD1/5/8. CMF9 downregulates the expression of fibrotic markers α-SMA and COL1A1. CMF9 exhibits potent anti-fibrotic effects in mouse models by promoting the degradation of pathological extracellular matrix (ECM) and inhibiting inflammation. CMF9 can be used for the study of liver fibrosis[1].
UNSPSC
12352209
Target
TGF-beta/Smad
Related Pathways
Stem Cell/Wnt; TGF-beta/Smad
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
O=C(N[C@@H](CCCNC(N)=N)C(N1[C@@H](CCC1)C(N[C@@H](C)C(N[C@@H](CO)C(N[C@H](CC2=CC=CC=C2)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(N[C@@H](CCC(O)=O)C(N[C@@H]([C@H](O)C)C(N[C@H]5CO)=O)=O)=O)=O)=O)=O)=O)=O)[C@H]([C@H](O)C)NC5=O
Molecular Formula
C53H74N14O16
Molecular Weight
1163.24
References & Citations
[1]Cheng W, et al. Discovery of Novel Cyclic Peptides as SMAD2-SMAD4 Interaction Inhibitors for the Treatment of Hepatic Fibrosis. J Med Chem. 2025 May 22;68 (10) :9958-9972.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported

Popular Products